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Short title:  Quality of life in overweight survivors in a weight loss trial 
 





Objective: To examine the correlates of the physical and psychosocial domains of 
quality of life (QOL) in a cohort of breast cancer survivors participating in a weight loss 
intervention trial.   
Methods:  Correlates of QOL and psychosocial functioning were examined in 692 
overweight/obese breast cancer survivors at entry into a weight loss trial.  QOL was 
explored with three measures: Short-form 36 (SF-36); Impact of Cancer Scale (IOCv2); 
and the Breast Cancer Prevention Trial (BCPT) Symptom Scales.  Available data 
included information on weight and physical activity, as well as demographic and 
medical characteristics.  Multivariate analyses were used to identify associations 
adjusted for other characteristics.  
Results:  In multivariate analysis, younger age was associated with higher negative 
impact scores (p < 0.0001).  Hispanic, African-American and Asian women had higher 
positive IOC impact scores compared to white non-Hispanic women (p < 0.01).  
Increased number of co-morbidities was associated with lower physical and mental 
QOL scores (p < 0.01).  BMI was not independently associated with QOL measures.  
Physical activity was directly associated with physical and mental QOL and IOC positive 
impact, and inversely related to IOC negative impact and BCPT symptom scales. 
Conclusions: QOL measures in breast cancer survivors are differentially associated with 
demographic and other characteristics.  When adjusted for these characteristics, degree 
of adiposity among overweight/obese women does not appear to be independently 
associated with QOL.  Among overweight/obese breast cancer survivors, higher level of 









Breast cancer diagnosis and treatment is associated with adverse health effects 
in physical and psychosocial domains, and thus, can have a negative impact on quality 
of life (QOL) [1].  Although most symptoms show improvement over time [2], some may 
be long-term, lasting for up to 10 years after surgery and completion of treatment [3].  
Among psychosocial correlates, depression and anxiety are often associated with 
poorer QOL either as indicators [4] or determinants.  Sleep problems and fatigue have 
also been identified as being associated with poorer QOL [5], as well as weight gain 
after treatment [6], and often these symptoms are interrelated [7]. 
In a systematic review, Chopra and Kamal [8] concluded that age, ethnicity, and 
type of treatment influence different aspects of QOL.  Similarly, differential effects of 
treatment on QOL have been noted for race/ethnicity, and age [9-12].  Based on a 
comprehensive literature review, Yanez et al. [13] concluded that Latina survivors 
experience worse QOL than non-Latina whites, but White et al. [14] caution that racial 
differences may be better explained by the variance in levels of engagement in healthy 
behaviors.  Concerns and adverse effects may be particularly notable for younger 
survivors who report more adverse psychosocial and health outcomes [3, 15].  
Premature menopause is thought to exacerbate the effects of treatment among these 
younger women [16]. 
Obesity and weight gain, as indicated by high body mass index (BMI), has been 
associated with worse QOL among breast cancer survivors [15, 17].  Post-diagnosis 
physical activity has been identified as a protective factor that may mitigate common 
side effects such as fatigue and weight gain [18] and improve overall QOL [19].  In a 
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large randomized clinical trial of breast cancer survivors, participants who exercised at 
least 150 minutes/week of moderate-paced walking reported significantly higher levels 
of QOL independent of race/ethnicity [11]. 
The purpose of this analysis was to examine the correlates of QOL and 
psychosocial functioning in overweight or obese breast cancer survivors using data 
collected upon entry into a weight loss intervention trial.  The multi-center Exercise and 
Nutrition to Enhance Recovery and Good Health for You (ENERGY) study is the largest 
weight loss study in this patient population to date, enrolling 692 overweight or obese 
women who had been diagnosed and treated for early stage breast cancer [20].  Within 
this large and well-characterized sample, different aspects of QOL were explored with 
three measures: the Short-form 36 (SF-36) [21] as a general measure of physical and 
mental QOL; Impact of Cancer Scale (IOCv2) to assess QOL and both positive and 
negative aspects of cancer survivorship [10]; and the Breast Cancer Prevention Trial 
(BCPT) Symptom Scales to evaluate side effects of treatment [22].  We hypothesized 
that responses on the QOL measures would be differentially distributed across level of 
adiposity, as well as age, race/ethnicity, cancer stage and treatment, number of co-
morbidities, and level of physical activity. 
Methods 
Participants and study procedures 
A total of 692 overweight or obese breast cancer survivors were enrolled into a 
randomized controlled trial of a weight loss intervention, the Exercise to Enhance 
Recovery and Good Health for You (ENERGY) trial, at four sites (San Diego, CA; 
Denver, CO; St. Louis, MO; and Birmingham, AL).  Inclusion criteria were: age >21 
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years; a history of breast cancer (stages I [≥1 cm], II, or III) diagnosed within the 
previous five years; completion of initial therapies not including endocrine therapy; BMI 
25-45 kg/m2; and ability to comply with study procedures.  Exclusion criteria included: 
history of malignancies other than initial breast cancer with the exception of non-
melanoma skin cancer, serious psychiatric illness, and any medical condition 
substantially limiting moderate physical activity, such as severe orthopedic conditions. 
The study was reviewed and approved by the Institutional Review Boards of all sites, 
and participants provided written informed consent.  A detailed description of the study 
procedures and intervention has been published previously [20]. 
Measures 
Demographic and other characteristics   
Data included self-reported age, race/ethnicity, education level, marital status, 
and medical history (including co-morbidities).  Anthropometric measurements (height, 
weight) were conducted by trained study staff using standard procedures and were 
used to calculate BMI [23].  Medical record review was conducted to obtain information 
on breast cancer diagnosis including stage and date of diagnosis and treatment and to 
verify eligibility.   
Physical activity was measured using the modified Godin Leisure-Time Exercise 
Questionnaire (GLTEQ) which has been validated previously in cancer research [24]. 
The modified GLTEQ consists of three questions regarding the frequency and duration 
of mild, moderate, and strenuous exercise performed during free time in a typical week. 
Risk for depression was measured with the Center for Epidemiologic Studies 
Depression Scale (CES-D).  The CES-D is comprised of 20 items and assesses risk for 
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depression in the general population [22].  Measures of internal consistency are high in 
the general population (0.85) and in psychiatric samples (0.90).  Test-retest correlations 
are reported to be in the moderate range (0.45-0.70).  Validity has been established 
with other self-report measures, correlations with clinical ratings of depression, and by 
construct validity [25].  It has also been used in other studies of cancer survivors [26]. 
Self-reported information on co-morbidities was collected with a questionnaire 
modeled after the Self-Administered Co-morbidity Questionnaire [27].  Number of 
reported co-morbidities (e.g., heart disease, hypertension, lung disease, diabetes, ulcer 
or stomach disease, kidney disease, liver disease, anemia, depression, osteoarthritis, 
back pain, rheumatoid arthritis, or other) was summed.   
Psychosocial QOL measures 
The SF-36 is a multi-purpose, brief health survey, which is used as a general 
measure of physical and mental QOL [21, 28].  It is comprised of an 8-scale profile of 
functional health and well-being scores as well as psychometrically-based physical and 
mental health summary measures.  There is considerable evidence for the reliability of 
the SF-36 (Cronbach’s α>0.85, reliability coefficient >0.75) [28, 29].  It has been used 
extensively with breast cancer survivors [5, 6, 26]. 
 The BCPT Symptom Scales have been used to measure concurrent and late 
side effects of medical interventions to prevent and treat breast cancer [22].  Factor 
analysis with this instrument [22] has revealed eight symptom clusters corresponding to 
physical symptoms associated with cancer treatment, chemoprevention, menopause, 
and normal aging: hot flashes, nausea, bladder control, vaginal problems, 
musculoskeletal pain, cognitive problems, weight problems, and arm problems. 
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 The IOC was developed specifically to measure the impact of cancer on aspects 
of QOL in long term survivors (i.e. > 5 years since diagnosis) [10].  Recent refinement of 
this instrument in a large sample of long-term breast cancer cancer survivors (ref 10)  
yielded a factor structure relating IOC items to psychosocial impact domains that 
exhibited high factor loadings (factor-item correlations of 0.59-0.94) and high internal 
consistency (Cronbach’s α=0.76-0.89).  The scales consist of a Positive Impact 
Summary Scale with four subscales (altruism and empathy, health awareness, meaning 
of cancer, and positive self-evaluation), a Negative Impact Summary Scale with four 
subscales (appearance concerns, body change concerns, life interferences, and worry), 
and subscales for Employment and Relationship Concerns.  
Statistical analysis 
 For the five overall QOL outcome measures (summary scores for physical and 
mental QOL, IOC positive and negative impact scales, and mean severity averaged 
across all 18 symptoms on the BCPT questionnaire), bivariate analyses were used to 
examine associations with the a priori hypothesized influencing variables (BMI, age, 
race/ethnicity, cancer stage and treatment, number of co-morbidities, and level of 
physical activity) and exploratory variables (education, marital status, and time since 
diagnosis). We hypothesized that greater degree of adiposity (higher BMI), younger 
age, higher stage, chemotherapy, and number of co-morbidities would be associated 
with worse physical and mental QOL, higher IOC negative impact, and greater BCPT 
symptoms.  We also hypothesized that higher physical activity would be inversely 
associated with these measures. 
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  Continuous variables (age, BMI, number of co-morbidities, weekly hours of 
moderate/vigorous activity, and CES-D score) were modeled in continuous ANOVA.  
Categorical variables (race/ethnicity, cancer stage, chemotherapy, endocrine therapy, 
education, marital status) were compared using categorical ANOVA where the first 
category was the referent.  Implementing a conservative strategy, we used a 
significance level of alpha = 0.01 for the bivariate models, and p ≤ 0.05 in the 
multivariate model, without further adjustment for multiple comparisons.  All tests were 
two-sided.  
 Multivariate models for four of the main outcomes (physical and mental QOL and 
IOC positive and negative impact scale) used regression models to examine 
relationships between the predictors jointly and outcomes. The multivariate analyses 
included all variables that were a priori hypothesized predictors, as well as the 8 BCPT 
symptom clusters, but did not include the exploratory variables.  Dependent variables 
were log transformed to reduce skew in their distributions.  
We also evaluated the four subscales each from the IOC Positive and Negative 
Impact Scales separately.  We set significance at p < 0.01 for the subscale analyses.  
Analyses were conducted using SAS version 9.3 (Cary, NC). 
Results 
Participants were 692 overweight or obese breast cancer survivors with a mean 
(SD) age of 56 (9) years at enrollment.  Characteristics of the study sample and 
distribution of scores across the QOL measures are shown in Tables 1 and 2.  The 
majority of the sample was non-Hispanic white, and BMI at study entry was 31.4 (4.7) 
kg/m2.  On average, time since diagnosis was 2.7 years (range 0.25-5.8 years).  A 
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majority of the women had been diagnosed with stage II cancer (52%), and 30% and 
18% had stage I and stage III cancer, respectively.  
In bivariate analysis, responses on the QOL measures were differentially 
distributed across categories of demographic characteristics, as shown in Table 1.  QOL 
measures differed across age, BMI, and race/ethnicity categories.  Compared to white, 
non-Hispanic participants, Hispanic, African-American and Asian participants all 
reported higher scores on the IOC positive impact scale (p < 0.01).  Responses on the 
QOL measures also were differentially distributed across categories of medical and 
cancer-related factors, as shown in Table 2.  Having more co-morbidities was 
associated with lower physical and mental QOL scores (p < 0.01). 
Differential responses on the QOL measures across physical activity and CES-D 
score categories are shown in Table 3.  Being moderately active, as is recommended 
for weight management [30], was associated with better scores on the physical and 
mental QOL scales (p < 0.01), and a dose-response effect was observed.  Higher level 
of physical activity was associated with lower scores on the IOC negative impact scale 
(p < 0.01) and with lower scores on the BCPT symptoms scales (p < 0.01).  The reverse 
was true for those who had higher scores (≥16) on the CES-D.  Those at higher risk for 
depression had lower scores on physical and mental QOL and higher scores on the 
BCPT symptom scales (p < 0.01). 
 Table 4 shows the associations for the a priori hypothesized variables when 
adjusted for other influencing variables in the multivariate models.  Younger age was 
associated with higher IOC negative impact scale (p < 0.0001).  Hispanic, African-
American and Asian women had higher scores on the IOC positive impact scale 
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compared to white, non-Hispanic women, and African-American women scored lower 
on the IOC negative impact scale (p < 0.01).  Number of co-morbidities and several 
BCPT symptom clusters were associated with lower physical and mental QOL (p < 
0.02), when adjusted for other variables.   
Contrary to our hypothesis, BMI was not independently associated with any of 
the QOL measures in the multivariate models.  As hypothesized, level of physical 
activity was associated with physical and mental QOL (p < 0.01).  Women with higher 
levels of depressive symptoms on the CES-D had significantly lower physical QOL, 
lower IOC positive impact and higher IOC negative impact scores (p <0.001). 
As shown in Table 4, the BCPT symptom scale for nausea was inversely 
associated with both physical and mental QOL (p < 0.01).  The BCPT scale for bladder 
control was inversely associated with mental QOL, and the musculoskeletal pain scale 
was inversely associated with physical and mental QOL (p < 0.02).  Cognitive problems 
were inversely associated with mental QOL, and directly associated with both IOC 
positive and negative impact scores.  The BCPT symptom scale for weight problems 
was inversely associated with mental QOL and directly associated with the IOC 
negative impact scores (p < 0.01).  The BCPT arm problems scale was inversely 
associated with physical QOL scores, meaning lower severity of arm problems was 
associated with better physical QOL scores, and directly associated with the IOC 
negative impact scale (p < 0.001).  Two of the symptom scales (vasomotor and vaginal 
problems) were not significantly associated with any of the QOL outcomes. 
Associations with the subscales of the IOC negative and positive impact score 
also were examined (data not shown), and cancer stage was directly associated with 
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scores for each negative impact subscale (p < 0.01).  In contrast, age and African-
American ethnicity were inversely associated with every subscale score.  Age was 
inversely associated with altruism and meaning of cancer subscale scores.  African-
American, Asian and Hispanic race/ethnicity were all directly associated with health 
awareness and positive self-concerns subscales.  In addition, being African-American 
was associated with greater meaning of cancer, while being Asian was associated with 
altruism.  Chemotherapy was directly associated with scores for all four IOC positive 
impact subscales (p < 0.01 for all). 
Discussion 
We found that various dimensions and measures of QOL in breast cancer 
survivors are differentially associated with demographic and medical characteristics.  
After adjusting for these characteristics, contrary to our hypotheses, degree of adiposity 
had no relationship to any of the QOL outcomes in the multivariable models, although 
BMI was inversely associated with physical (but not mental) QOL when unadjusted for 
other influencing variables.  However, we found that among overweight or obese breast 
cancer survivors, higher level of physical activity correlates with higher mental and 
physical QOL and does so in a dose-dependent manner. 
This analysis presents a multifaceted approach to examining QOL in a large and 
geographically-diverse sample of overweight or obese breast cancer survivors.  By 
utilizing several different measurement constructs, this study provides a global 
examination of the psychosocial and physical QOL associations in this target 
population.  In particular, this is the first study, to our knowledge, to have used the IOC 
in shorter-term breast cancer survivors, along with the SF-36 and the BCPT symptom 
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scales. In addition to the large sample, the diversity of the sample also allowed analysis 
of findings for various subgroups, such as older versus younger survivors or those with 
different racial/ethnicity and cancer characteristics.  
The characteristics that were found to impact QOL in the current study can be 
compared to those reported in other studies with breast cancer survivors, and confirm 
and expand upon what has been observed in other reports.  Using the SF-36, Bowen et 
al. [9] concluded that participants in the HEAL study were doing relatively well two years 
after diagnosis, even though some racial/ethnic and socioeconomic differences were 
identified as important determinants of QOL.  Utilizing the BCPT Symptom Scales, 
Ganz et al. [1] noted that even though overall functioning improved after breast cancer 
treatment, those who received chemotherapy reported more severe physical symptoms 
such as vaginal and weight problems. 
In this study, age at diagnosis and non-white race/ethnicity (Hispanic, African-
American or Asian) were identified as independently associated with QOL in breast 
cancer survivors, with younger women experiencing more negative impact from the 
cancer and non-white women noting more meaning and positive impact from the cancer 
experience.  This is consistent with other studies in the literature, although this study is 
notable for assessing these issues in a group of women earlier in the post-treatment 
phase of survivorshipAlthough younger participants noted some positive outcomes from 
their experience on the IOC measure (i.e., becoming more health aware, valuing their 
relationships more), our results suggest that their overall outlook on body changes was 
more negative, and they reported more health-related worries and treatment-related 
symptoms.  This observation held true in IOC subscale analysis as well. In another 
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sample of breast cancer survivors, Crespi et al. [11] also found younger women to have 
somewhat higher scores on both positive and negative IOC scores, and results from 
previous studies indicate that survivors <50 years of age report concerns about 
premature menopause and infertility, physiologic symptoms such as night sweats and 
hot flashes, weight gain, and adverse psychosocial outcomes, such as depressive 
symptoms [15, 16].  Future studies that focus on identifying effective strategies to 
improve QOL in this vulnerable group of survivors are clearly warranted. 
Racial/ethnic minority participants reported higher IOC positive and negative 
impact scores which may indicate willingness to see cancer as a positive life challenge, 
such as having more health awareness and positive self-concerns as identified by IOC 
subscale analysis.  Other studies have noted greater meaning and personal growth 
among African-American breast cancer survivors [31, 32], and better QOL.  Different 
levels of QOL for survivors with diverse racial and ethnic backgrounds have been 
identified in prior studies [13]. 
The association between degree of adiposity (reflected in the BMI) and better 
physical QOL in the bivariate analysis did not remain significant in the multivariate 
model, although at enrollment in this study, none of the participants was in the healthy 
weight range.  In another sample of breast cancer survivors, higher BMI was associated 
with higher IOC negative impact and subscales [11], but that observation was not 
adjusted for other influencing factors as in the present study.  There is evidence in the 
literature that maintaining a healthy weight is an independent factor for better prognosis 
of breast cancer [33, 34], as well as for better overall physical functioning and 
management of treatment side effects such as sleep and mood problems [6].  However, 
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results of this analysis suggest that in overweight or obese women, co-morbidities and 
other factors are crucial determinants of QOL. 
As in the present study, Ashing-Giwa and Lim [35] found that having fewer co-
morbidities were related to better mental and physical QOL in a diverse group of breast 
cancer survivors.  This is an important finding because it suggests that overweight or 
obese breast cancer survivors who can lose enough weight to impact co-morbidities, 
even if they do not achieve an optimal weight, may improve QOL.  Ganz et al. [1] found 
that even though physical and social functioning improves after treatment, physical 
symptoms persist for those who have received chemotherapy for up to a year.  
Similarly, in the current study, participants indicated experiencing lower mental and 
physical QOL in association with a myriad of symptoms such as nausea, bladder control 
issues, and musculoskeletal and arm problems.  That these factors are contributing to 
lower mental and physical QOL is an important finding, and attention to symptom 
control could be important for improving QOL outcomes. 
Multivariate models in this study revealed that more physical activity in these 
overweight or obese women was related to better overall QOL, having a more positive 
outlook on life, as well as having fewer health-related worries and treatment-related 
symptoms.  In fact, our observations suggest that any amount of exercise is better than 
none.  In contrast, higher depressive symptomatology scores were associated with 
lower physical QOL scores, as well as lower positive impact and higher negative impact 
IOC scores, as previously observed in this target population [11].  Although this analysis 
uses cross-sectional data that cannot imply causality, previous interventions have 
shown that exercise has positive impact on overall QOL [36] and also depressive 
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symptoms [37, 38] and fatigue [39].  Regular physical activity after breast cancer 
diagnosis and treatment also may mitigate common side effects of adjuvant therapy, 
such as weight gain and fatigue [36], depression, reduced QOL, as well as decreased 
muscular strength [40]. 
Results of this study present important evidence of symptom burden following 
treatment in overweight or obese breast cancer survivors.  However, this study also has 
limitations.  Even though the large sample size allowed for subgroup analysis, the study 
sample was nonetheless largely homogeneous, so results may not be entirely 
representative of the general population of breast cancer survivors.  Nevertheless, most 
breast cancers are diagnosed in overweight or obese women, and our sample had more 
diversity than most other studies in this research area.  It is important to examine these 
constructs in an even more diverse sample of breast cancer survivors, particularly 
among those across an even wider range of BMI, including lean women.  Additionally, 
we have not addressed all potential confounding influences, such as income [35], 
location of treatment (e.g., academic centers, community- or hospital-based practices), 
or rural vs. urban environment.  Finally, the relationship between depression and QOL is 
not straightforward, and future research should examine the impact of these variables 
on QOL.  Future research is needed to examine this complex association in cancer 
survivors to determine if depression is an indicator or determinant of QOL. 
These baseline findings set the stage for the longitudinal evaluation of QOL 
outcomes in this study sample.  In future analyses we can examine whether increased 
physical activity and weight loss have a positive impact on QOL and improve long term 
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Age at enrollment (yrs)       
 <50 173 70.4 (19.5) 73.4 (19.2) 3.9 (0.5)* 2.9 (0.8)* 2.1 (0.6)* 
 50-64 372 71.8 (18.4) 76.0 (18.0) 3.8 (0.6)* 2.7 (0.7)* 2.1 (0.5)* 
 ≥65 147 67.7 (17.8) 77.2 (16.4) 3.7 (0.5)* 2.4 (0.7)* 1.9 (0.5)* 
Body mass index (kg/m2)       
 25-29.99 285 72.3 (17.9)* 75.9 (17.9) 3.8 (0.6) 2.7 (0.7) 2.0 (0.5) 
 30-34.99 243 70.5 (18.8)* 74.7 (18.5) 3.8 (0.6) 2.6 (0.7) 2.0 (0.5) 
 35-45 164 67.6 (19.2)* 76.3 (17.5) 3.8 (0.6) 2.6 (0.7) 2.1 (0.6) 
Race/ethnicity       
 White, non-Hispanic 547 70.8 (17.7) 75.9 (17.3) 3.8 (0.5) 2.7 (0.7) 2.0 (0.5) 
 Hispanic 46 68.9 (19.2) 70.3 (21.5) 4.0 (0.5)* 2.8 (0.7) 2.1 (0.6) 
 African-American 71 67.9 (24.3) 75.2 (21.1) 4.0 (0.6)* 2.5 (0.8) 2.2 (0.6) 
 Asian 11 76.8 (13.9) 82.1 (11.5) 4.3 (0.3)* 2.8 (0.6) 1.7 (0.3) 
 Mixed/other  15 74.1 (18.4) 76.3 (17.7) 3.9 (0.6) 2.7 (0.7) 1.9 (0.4) 
Education       
 Not a college graduate 282 70.6 (18.5) 76.0 (17.5) 3.9 (0.5)* 2.6 (0.7) 2.1 (0.5) 
 College graduate  410 70.5 (18.7) 75.3 (18.3) 3.7 (0.6)* 2.7 (0.7) 2.0 (0.6) 
Marital status       
 Married/partnered 463 72.0 (17.7) 77.1 (17.5) 3.8 (0.6) 2.7 (0.7) 2.1 (0.5) 
      Not married or partnered 228 67.6 (20.1)* 72.5 (20.4)* 3.8 (0.6) 2.7 (0.8) 2.0 (0.5) 
 
a Values shown are mean (SD). 
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* p < 0.01; continuous variables (age and body mass index) were modeled in continuous ANOVA, and categorical variables were 
compared using categorical ANOVA where the first category was the referent.  
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Time since diagnosis       
 <1 year 76 66.1 (21.1)* 70.5 (21.2)* 3.9 (0.6) 2.7 (0.7) 2.1 (0.6) 
 1-2.9 years 325 69.5 (18.9)* 75.0 (17.6)* 3.8 (0.6) 2.7 (0.7) 2.1 (0.5) 
 ≥3 years 291 72.9 (17.2)* 77.5 (17.2)* 3.8 (0.6) 2.6 (0.7) 2.0 (0.6) 
Cancer stage       
 I 210 73.3 (17.5) 77.2 (17.6) 3.7 (0.6) 2.5 (0.7) 2.0 (0.5) 
 II 358 70.7 (18.8) 75.4 (18.0) 3.8 (0.6)*  3.0 (0.7)* 2.1 (0.6) 
 III 124  65.4 (18.8)* 73.3 (18.4) 3.9 (0.5)  2.9 (0.7)*  2.1 (0.5)* 
Chemotherapy       
 No 165 73.5 (17.5) 76.6 (18.3) 3.6 (0.6) 2.5 (0.7) 1.9 (0.5) 
 Yes 527 69.6 (18.8) 75.3 (17.9) 3.9 (0.5)*  2.7 (0.7)*  2.1 (0.6)* 
Endocrine therapy       
 None 179 69.0 (19.6) 74.2 (19.3) 3.8(0.6) 2.8 (0.8) 2.0 (0.5) 
 Anti-estrogen only 147 71.5 (20.4) 75.4 (17.5) 3.9 (0.5) 2.7 (0.7) 2.1 (0.6) 
 Aromatase inhibitor 366 70.9 (17.3) 76.3 (17.5) 3.8 (0.6) 2.6 (0.7) 2.1 (0.6) 
Co-morbiditiesb       
 None 253 75.7 (16.2)* 78.2 (16.0) * 3.9 (0.5) 2.6 (0.7) 2.0 (0.6)* 
 1 240 70.5 (18.2)* 76.2 (17.3)* 3.7 (0.6) 2.7 (0.7) 2.0 (0.5)* 
 2 119 67.5 (18.4)* 74.0 (18.6)* 3.8 (0.6) 2.6 (0.7) 2.9 (0.5)* 
 3 or more 80 59.0 (21.1)* 67.7 (22.2)* 3.8 (0.6) 2.7 (0.8) 2.2 (0.6)* 
 
a Values shown are mean (SD). 
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b  Co-morbidities assessed are current treatment for heart disease, hypertension, lung disease, diabetes, ulcer or stomach disease, 
kidney disease, liver disease, anemia, depression, osteoarthritis, back pain, rheumatoid arthritis and other conditions.  
* p < 0.01, continuous variables were modeled in continuous ANOVA, and categorical variables (cancer stage, chemotherapy, and 
endocrine therapy) were compared using categorical ANOVA where the first category was the referent.   
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Moderate/vigorous activity, hrs/wk       
 None 284 65.9 (19.6)* 72.3 (19.0)* 3.8 (0.6) 2.7 (0.7)* 2.1 (0.5)* 
 0.1-0.9  70 69.0 (18.8)* 73.8 (17.0)* 3.8 (0.5) 2.9 (0.7)* 2.1 (0.6)* 
 1-2.9 208 73.6 (16.6)* 77.1 (16.7)* 3.8 (0.6) 2.6 (0.7)* 2.0 (0.5)* 
 3 or more 130 76.6 (16.8)* 81.3 (16.8)* 3.9 (0.6) 2.6 (0.7)* 1.9 (0.6)* 
CES-D score       
 Not depressed (0-15) 555 73.9 (16.6)* 81.0 (12.6)* 3.8 (0.6) 2.5 (0.6)* 1.9 (0.5)* 
 At risk for depression (≥16) 137 57.1 (20.1)* 53.7 (19.8)* 3.8 (0.6) 3.3 (0.8)* 2.5 (0.5)* 
 
a Values shown are mean (SD). 
*p < 0.01.   
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Table 4. Multivariate models for quality of life (QOL) measures in overweight/obese breast cancer survivors (N = 692)a 
 
 
QOL Physical                             
R2=0.43 
 
QOL Mental  
R2=0.30 
IOC Positive 
 Impact Scale  
R2=0.11 
IOC Negative 



















Age -.001 .55 .002 .15 -.004 .12 -.011 <.0001 
Body mass index -.003 .20 .003 .28 -.000 .95 -.009 .08 
Race/ethnicity         
       African-American .002 .94 -.027 .50 .269 .0002 -.396 <.0001 
 Asian .018 .81 .018 .84 .538 .001 .173 .33 
 Hispanic -.003 .94 -.056 .22 .233 .006 .090 .32 
Cancer stage -.027 .10 -.013 .49 -.003 .92 .125 .0008 
Chemotherapy .022 .40 .037 .22 .233 <.0001 .023 .69 
Any endocrine therapy .032 .16 .029 .28 .046 .34 -.092 .08 
No. of co-morbidities  -.040 <.0001 -.032 .006 -.012 .58 .024 .30 
Moderate/vigorous activity .012 .006 .014 .01 .010 .29 -.002 .82 
CES-D Score* -.009 <.0001 x x -.012 .001 .031 <.0001 
BCPT symptom clusters          
       Hot flashes -.005 .55 .002 .84 .015 .44 .010 .63 
 Nausea -.083 .002 -.086 .005 -.061 .27 .031 .60 
 Bladder control .011 .36 -.028 .05 .003 .91 .021 .45 
       Vaginal problems .013 .12 .006 .53 .001 .94 .021 .28 
 Musculoskeletal pain -.128 <.0001 -.032 .02 -.001 .96 .048 .09 
 Cognitive problems -.016 .23 -.124 <.0001 .081 .004 .064 .04 
 Weight problems -.006 .54 -.041 .0009 -.012 .60 .112 <.0001 




a Values shown are ß coefficients and p values for associations with each of the four outcomes, when controlled for all variables 
tabulated.  Quality of life outcomes were log transformed 
* CES-D score was omitted as a predictor for QOL Mental because of high correlation between the two (rho = -0.72). 
 
